AU2005311321A1

AU2005311321A1 - G protein coupled receptor

Info

Publication number: AU2005311321A1
Application number: AU2005311321A
Authority: AU
Inventors: Bernard Coulie; Inge Irma Therese Depoortere; Diederik Willem Elisabeth Moechars; Benoit Christian Jean-Claude Moreaux; Theophiel Louis Henri Peeters
Original assignee: Janssen Pharmaceutica NV
Current assignee: Janssen Pharmaceutica NV
Priority date: 2004-12-01
Filing date: 2005-11-30
Publication date: 2006-06-08
Also published as: WO2006058889A1; CN101107529A; RU2007124609A; JP2008521419A; EP1820026A1; CA2587534A1; ZA200704526B; NO20073294L; KR20070086003A

Description

WO 2006/058889 PCT/EP2005/056350 -1 G PROTEIN COUPLED RECEPTOR Field of the Invention 5 The present invention relates to the functional characterization of the G protein coupled receptor GPR39 and to compounds, which modify or regulate GPR39 protein activity. In particular the present invention relates to methods of screening for agonists or antagonists of GPR39 10 in order to identify Gastrointestinal Kinetics regulating agonists or antagonists and to the therapeutic uses of these compounds. In another embodiment the present invention relates to the involvement of GPR39 in metabolism homeostasis, in particular on the cholesterol 15 levels observed in the GPR39 knockout mice. The invention also relates to transgenic animals bearing mutations in the GPR39 gene. Background to the Invention 20 GTP-binding proteins (G proteins) act as intermediaries between binding of ligands such as hormones and other chemical mediators to G protein coupled receptors (GPCRs) and activation of intracellular effectors. Upon binding of 25 a ligand to a GPCR, the cytoplasmic domains of the receptor undergo conformational changes, which enable interaction of the receptor with a G protein, which in turn enables activation of intracellular intermediaries such as adenylate cyclase, phospholipase C or ion 30 channels. Such a system allows amplification of the original signal as many second messengers can be produced in response to the binding of a single ligand at the GPCR. Through this mechanism, cells are able to sense and respond to alterations in their external environment. 35 WO 2006/058889 PCT/EP2005/056350 -2 G protein coupled receptors form a superfamily of integral plasma membrane proteins, each receptor sharing the common feature of seven hydrophobic transmembrane domains, each of which is 20 -30 amino acids long and which are linked 5 by hydrophilic amino acid sequences of varied length. The amino terminus of the receptor is extracellular with the carboxy terminus found in the cytoplasm of the cell. GPCRs are found in a wide range of tissues and cell types 10 and are involved in many different physiological processes. They are activated by a broad range of ligands, for example, hormones such as luteinizing hormone, follicle stimulating hormone, chorionic gonadotrophin, thyrotropin, adrenocorticotrophin, glucagon and 15 vasopressin; neurotransmitters such as 5-HT, acetylcholine (muscarinic AchR), histamine, prostaglandins, calcitonin, leukotrienes and Ca . The broad distribution and wide variety of roles of GPCRs indicate that GPCRs may play important roles in a variety of pathological conditions. 20 Indeed, GPCRs have been found to be involved in diseases related to bronchoconstriction, hypertension, inflammation, hormonal disturbance, diabetes, apoptosis, nociception, facilitation of neurotransmission and tremor disorders. 25 Within the G-protein-coupled receptor superfamily, the putative GPCRs for which the natural ligands are unknown are called "orphan receptors". G protein-coupled receptor have been proven to be valuable drug targets, since they 30 are the target of about 50% of the marketed drugs. Therefore many orphan GPCR are being evaluated to identify new potential targets. GPR39 was identified based upon is sequence similarity 35 with the growth hormone secretagogue receptor (GHS-R) and WO 2006/058889 PCT/EP2005/056350 -3 the neurotensin receptors 1 and 2 (NT-Ri and NT-R2) (McKee et al., 1997). The predicted 453-amino acid GRP39 protein contains the 7 transmembrane domains characteristic of GPCRs. By sequence comparison with other GPCRs, McKee et 5 al. (1997) found that the protein sequence of GPR39 is 27%, 29% and 32% identical to that of GSHR, MTLR1 (motilin receptor) and neurotensin receptor-1, respectively. Northern blot analysis revealed that GPR39 has a wide tissue distribution. A single hybridizing mRNA transcript 10 of 1.8-2 kb, was detected in most brain regions tested. However, in addition to this species, an alternate transcript, 3-kb in length, was observed in several peripheral tissues such as stomach and small intestine, and in tissues such as pancreas, thyroid and colon, this 15 3-kb species was the only transcript detected (McKee et al., 1997). By fluorescence in situ hybridization, McKee et al. (1997) mapped the GPR39 gene to 2q21-q22. An acidic residue in TM3, essential for the binding and activation of the GHS-R by structurally dissimilar GHSs, is conserved 20 in GPR39. Based on these tissue distribution studies GPR39 has been hypothesized to be involved in cardiovascular disease states (W02001/081634 & W02004/004279), cancers and in 25 particular brain cancers such as glioblastoma (W02001/036685 & W001042288), inflammation and neurological disease states (US 2003/ 232769 & W02004/004279) and in gastrointestinal and liver diseases (W02004/004279). Nonetheless, in none of the cited 30 references a functional characterization based on ligand identification for GPR39 has been provided. For said reasons, the present functional annotation of GPR39 is speculative and requires further studies to identify the ligand-binding and functional properties of GPR39.

WO 2006/058889 PCT/EP2005/056350 -4 Given the wide tissue distribution of GPR39 and the fact that most G protein coupled receptors play an important role in a wide variety of cellular and physiological 5 processes, it would be interesting to gain an understanding of the normal physiological role of this receptor. Summary of the Invention 10 As noted above, the present invention concerns identification of novel functions of the GPR39 receptor. As shown in the examples hereinafter, GPR39 mutations in mammals affect gastric emptying and designate GPR39 as a 15 key element in the regulation of gastrointestinal kinetics. Given the fact that down regulation of the GPR39 gene leads to an increase in gastric emptying it is to be expected that an increase in GPR39 expression will attenuate gastric emptying. This discovery provides an 20 avenue for new therapeutic approaches in the regulation of gastrointestinal kinetics through modulation of GQPR39 activity. This discovery also provides new model systems for studying gastrointestinal kinetics and diseases involving gastrointestinal kinetics disorders, it also 25 provides for new screening methods for identifying compounds useful for the prevention or the treatment of these diseases. In addition to the above, phenotyping of the GPR39 30 knockout mice further revealed an involvement of this receptor on cholesterol metabolism. A down regulation of the GPR39 gene leads to increased cholesterol levels. It is accordingly to be expected that GPR39 will be involved in disease conditions with excess cholesterol levels such 35 as the metabolic syndrome, including obesity, diabetes, WO 2006/058889 PCT/EP2005/056350 -5 obesity related cardiovascular diseases, and glaucoma. Therefore, a first aspect of the invention provides for the use of all or part of GPR39 protein in a method for 5 identifying compounds that modulate gastrointestinal kinetics or which are effective for preventing and/or treating pathologies related with gastrointestinal kinetics disorders. In a further aspect the present invention provides the use of all or part of the GPR39 10 protein in a method to identify compounds that modulate cholesterol formation or which are effective for preventing and/or treating pathologies related with excess cholesterol formation. Alternatively, the invention provides for the use of cells expressing all or part of 15 the GPR39 protein in such method. In a specific embodiment GPR39 is an isolated protein having an amino acid sequence selected from the group consisting of SEQ ID No:2, SEQ ID NO:4, a splice variant of the proteins having the aforementioned SEQ ID's, and an amino acid sequence 20 having at least 50% and preferably at least 60%, 70%, 80%, 90%, 95% or 98% sequence identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. Parts of the GPR39 protein, as used hereinbefore, are 25 meant to include fragments of the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, said fragments being of at least 10, for example at least 20, 30 40, 50, 75, 100 or 150 or more amino acids in size. Such fragments may be derived from the N-terminal region of SEQ ID NO:2 or SEQ ID NO:4 30 respectively. Fragments including the N-terminal region may be used to reconstitute the extracellular portion of the receptor to provide receptor binding sites. Preferably, fragments will retain the ability to bind adenine. 35 WO 2006/058889 PCT/EP2005/056350 -6 The present invention also provides the use of an isolated nucleic acid sequence encoding all or part of the polypeptide of SEQ ID NO:2 or SEQ ID NO:4 in a method for identifying compounds that modulate gastrointestinal 5 kinetics or which are effective for preventing and/or treating pathologies related with gastrointestinal kinetics disorders and disease states related to high levels of cholesterol such as the metabolic syndrome, including diabetes and cardiovascular diseases. The 10 nucleic acid sequences as used in the methods of the present invention are meant to include the isolated nucleic acid sequences consisting of SEQ ID NO:l or SEQ ID NO:3, and nucleic acid sequences having at least 50% and' preferably at least 60%, 70%, 80%, 90%, 95% or 98% 15 sequence identity to the nucleic acid sequence of SEQ ID NO:l or SEQ ID NO:3. Nucleic acids of the invention further include nucleic acids which comprise a sequence having at least 50% and 20 preferably at least 60%, 70%, 80%, 90%, 95% or 98% sequence identity to the nucleic acid sequences of SEQ ID. NO: 1, or SEQ ID NO: 3 or their complements. Preferably, these sequences will hybridise to the corresponding nucleic acid under conditions controlled to minimise non 25 specific binding. Preferably stringent to moderately stringent hybridisation conditions are preferred. Suitable conditions include, e.g. for detection of sequences that are about 80-90% identical, hybridization overnight at 42 0 C in 0.25M Na 2

HPO

4 , pH 7.2, 6.5% SDS, 10% dextran sulfate 30 and a final wash at 55'C in 0.1X SSC, 0.1% SDS. For detection of sequences that are greater than about 90% identical, suitable conditions include hybridization overnight at 65 C in 0.25M Na 2

HPO

4 , pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60 0 C in 0.1X SSC, 0.1% 35 SDS.

WO 2006/058889 PCT/EP2005/056350 -7 It will be appreciated that such nucleic acids do not necessarily encode "full length" polypeptides, and will thus include nucleic acids which represent, for example, mutant forms of the GPR39 gene in which the coding 5 sequence has been prematurely terminated by either a substitution resulting in a stop codon or a frameshift mutation. These are also nucleic acids of the invention. The invention also provides the use of nucleic acids that 10 are fragments of the nucleic acids encoding a polypeptide of the invention. In one aspect, the invention provides nucleic acids primers which consist essentially of from 15 to 50, for example from 15 to 35, 18 to 35, 15 to 24, 18 to 30, 18 to 21 or 21 to 24 nucleotides of a sequence 15 encoding a polypeptide of the invention or its complement. Nucleic acids and polypeptides of the invention may be used therapeutically to treat disease. In particular, they may be used to treat diseases, the pathology of which is 20 associated with action at GPR39 receptors, particularly those associated with for preventing and/or treating pathologies related with gastrointestinal kinetics disorders and disease states related to increased cholesterol levels, such as the metabolic syndrome. 25 In a further aspect, there are provided vectors comprising the sequences of said nucleic acids, particularly expression vectors comprising a promoter operably linked to the nucleic acid sequences of the invention. The 30 vectors may be carried by a host cell, and expressed within said cell. Following said expression, said cells can be used in the methods according to the invention. As mentioned hereinbefore, it is an object of the 35 invention to provide assay methods for the identification WO 2006/058889 PCT/EP2005/056350 -8 of compounds (hereinafter also referred to as agents), which bind to or modulate the activity of polypeptides of the invention. In particular it is envisaged that such compounds are an organic or inorganic assembly of atoms of 5 any size, and includes small molecules (less than about 2500 Daltons) or larger molecules such as peptides, polypeptides, whole proteins and polynucleotides, wherein said compounds may be used in methods of treatment as described above. 10 As the present inventors are the first to identify GPR39 as a receptor as a key element in the regulation of gastrointestinal kinetics, the present invention opens up the possibility of using GPR39 itself and/or compounds 15 agonising or antagonising this receptor in therapeutic applications. Therefore the invention further extends to a method of treatment of a human or animal body, said method comprising the use of a GPR39 agonist or antagonist. In particular, a method of treating disease conditions 20 related with delayed gastric emptying such as for example, gastroparesis post-operative ileus, gastroparesis in diabetic, functional dyspepsia, post-vagotomy gastroparesis, slow transition constipation, constipation IBS, mixed-IBS and idiopathic intestinal pseudo 25 obstruction. Said method comprising administering to the human or animal a therapeutically active dosage of a GPR39 receptor antagonist, in particular comprising the use of a GPR39 antagonist identifiable using a method of the present invention. 30 It is also an object to provide a method of treating disease conditions related with increased gastric emptying such as for example, dumping syndrome or increased intestinal motility such as diarrhoea, diarrhoea-IBS and mixed IBS, said method comprising administering to the 35 human or animal a therapeutically active dosage of a GPR39 WO 2006/058889 PCT/EP2005/056350 -9 receptor agonist, in particular comprising the use of a GPR39 agonist identifiable using a method of the present invention. 5 In addition, based on the observed effect of the down regulation of the GPR39 receptor on cholesterol homeostasis, in a further aspect the present invention opens up the possibility of using GPR39 itself and/or compounds agonising or antagonising this receptor in 10 therapeutic applications with a defective cholesterol homeostasis. Therefore the invention also extends to a method of treatment of a human or animal body, said method comprising the use of a GPR39 agonists or antagonist in treating disease conditions related with a defective 15 cholesterol homeostasis. In particular the use of a GPR39 agonist in the treatment of disease conditions related with an excess cortisol formation such as the metabolic syndrome, including obesity, diabetes, and cardiovascular diseases such as atherosclerosis related to high levels of 20 cholesterol. These and other aspects of the invention are described herein in more detail. 25 Description of sequences. SEQ ID NO:l is the nucleotide sequence for mice GPR39. SEQ ID NO:2 is the amino acid sequence for mice GPR39. SEQ ID NO:3 is the nucleotide sequence for human GPR39. 30 SEQ ID NO:4 is the amino acid sequence for human GPR39. SEQ ID NO:5 is the GPR39 forward primer SEQ ID NO:6 is the GPR39 reverse primer SEQ ID NO:7 is a GPR39 probe sequence SEQ ID No:8 is human obestatin 35 SEQ ID No:9 is monkey obestatin WO 2006/058889 PCT/EP2005/056350 -10 SEQ ID No:10 is mouse obestatin SEQ ID No:11 is rat obestatin SEQ ID No:12 is gerbil obestatin SEQ ID No:13 is pig obestatin 5 SEQ ID No:14 is cat obestatin SEQ ID No:15 is dog obestatin SEQ ID No:16 is goat obestatin SEQ ID No:17 is sheep obestatin SEQ ID No:18 is Cattle obestatin 10 SEQ ID No:19 is the consensus sequence for obestatin Brief Description of the Drawings 15 Figure 1A Real-Time Quantitative Reverse Transcription PCR of GPR39 in tissues derived from wild type mice. Figure 1B Real-Time Quantitative Reverse Transcription PCR of GPR39 in four different tissues derived from wild type 20 mice and heterozygote and homozygote GPR39 knock-out mice. Figure 2 Comparison of the half emptying time (t 1 2 ) (A) and Tiag (B) for gastric emptying in GPCR39 knock-out mice vis-&-vis wild type mice. 25 Figure 3 Comparison of the faecal pellets propulsion in wild type mice (A) vis-&-vis GPCR39 knock-out mice (B). The distribution of pellets is counted in bins of 15% of total colon length and the number of pellets expelled from 30 each bin is counted during a 20 min time interval. Figure 4 Comparison of the cumulative food intake of not fasted mice (A) vis-&-vis fasted (19h) mice (B) for both young (17 weeks n=6) and older mice (56 weeks, n=6).

WO 2006/058889 PCT/EP2005/056350 -11 Figure 5 Amino acid sequence of preproghrelin from 11 mammalian species are shown with the signal peptide (italicized), mature ghrelin (shaded), and the flanking 5 obestatin (underlined). Consensus basic residues representing putative convertase cleavage sites are shown as white letters on a black background. In the consensus sequence, individual residues with complete conservation are shown in upper case. GenBank (gi) numbers for 10 individual ghrelin genes are 37183224 (human), 34541890 (monkey), 19224664 (mouse), 11067387 (rat), 27357900 (gerbil), 47523230 (pig), 52782813 (cat), 50978704 (dog), 52782814 (goat), 57526202 (sheep), and 27806613 (cattle). 15 Detailed Description of the Invention Nucleic acid 20 Nucleic acid as used in the methods of the present invention includes DNA (including both genomic and cDNA) and RNA. Where nucleic acid according to the invention includes RNA, reference to the sequences shown in the accompanying listings should be construed as reference to 25 the RNA equivalent, with U substituted for T. Nucleic acid of the invention may be single or double stranded. Single stranded nucleic acids of the invention include anti-sense nucleic acids. Thus it will be 30 understood that reference to SEQ ID NO:1 or sequences comprising SEQ ID NO:1 or fragments thereof include complementary sequences unless the context is clearly to the contrary. The same applies to SEQ ID NO:3. 35 Generally, nucleic acid according to the present invention WO 2006/058889 PCT/EP2005/056350 -12 is provided as an isolate, in isolated and/or purified form, or free or substantially free of material with which it is naturally associated, such as free or substantially free of nucleic acid flanking the gene in the human 5 genome, except possibly one or more regulatory sequence(s) for expression. Nucleic acid may be wholly or partially synthetic and may include genomic DNA, cDNA or RNA. The invention also provides nucleic acids that are 10 fragments of the nucleic acids encoding a polypeptide of the invention. In one aspect, the invention provides nucleic acids primers which consist essentially of from 15 to 50, for example from 15 to 35, 18 to 35, 15 to 24, 18 to 30, 18 to 21 or 21 to 24 nucleotides of a sequence 15 encoding a polypeptide of the invention or its complement. The term Aconsist essentially of~ refers to nucleic acids which do not include any additional 5' or 3' nucleic acid sequences. In a further aspect of the invention, nucleic 20 acids of the invention which consist essentially of from 15 to 30 nucleotides as defined above may however be linked at the 3' but preferably 5' end to short (e.g from 4 to 15, such as from 4 to 10 nucleotides) additional sequences to which they are not naturally linked. Such 25 additional sequences are preferably linkers which comprise a restriction enzyme recognition site to facilitate cloning when the nucleic acid of the invention is used for example as a PCR primer. 30 Primers of the invention are desirably capable of selectively hybridising to nucleic acids encoding the polypeptides of the invention. By Aselective~, it is meant selective with respect to sequences encoding other purine receptors and in particular with respect to WO 2006/058889 PCT/EP2005/056350 -13 receptors other than adenine receptors. The ability of the sequence to hybridise selectively may be determined by experiment or calculated. 5 For example, one way to calculate Tm of a primer is by reference to the formula for calculating the Tm of primers to a homologous target sequence. This formula is Tm(OC) = 2(A+T) + 4(G+C) - 5. This will provide the Tm under conditions of 3xSSC and 0.1% SDS (where SSC is 0.15M NaCl, 10 0.015M sodium citrate, pH 7). This formula is generally suitable for primers of up to about 50 nucleotides in length. In the present invention, this formula may be used as an algorithm to calculate a nominal Tm of a primer for a specified sequence derived from a sequence encoding 15 a polypeptide of the invention. The Tm may be compared to a calculated Tm for GPCR sequences of humans and rats, based upon the maximum number of matches to any part of these other sequences. 20 Suitable conditions for a primer to hybridise to a target sequence may also be measured experimentally. Suitable experimental conditions comprise hybridising a candidate primer to both nucleic acid encoding a polypeptide of the invention and nucleic acid encoding other adenine 25 receptors on a solid support under low stringency hybridising conditions (e.g. 6xSSC at 55 0 C), washing at reduced SSC and/or higher temperature, for example at 0.2xSSC at 45 0 C, and increasing the hybridisation temperature incrementally to determine hybridisation 30 conditions which allow the primer to hybridise to nucleic acid encoding a polypeptide of the invention but not other purine receptor encoding nucleic acids. Nucleic acids of the invention, particularly primers, may 35 carry a revealing label. Suitable labels include WO 2006/058889 PCT/EP2005/056350 -14 radioisotopes such as 32 P or 35 S, fluorescent labels, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers of the invention and may be detected using by techniques 5 known per se. Primers of the present invention may be comprised of synthetic nucleic acids, such as those with modified backbone structures intended to improve stability of the 10 nucleic acid in a cell. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes 15 of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or lifespan of polynucleotides of the invention. 20 Also included within the scope of the invention are antisense sequences based on the nucleic acid sequences described herein, preferably in the form of oligonucleotides, particularly stabilized 25 oligonucleotides, or ribozymes. Antisense oligonucleotides may be designed to hybridise to the complementary sequence of nucleic acid, pre-mRNA or mature mRNA, interfering with the production of 30 polypeptide encoded by a given target DNA sequence, so that its expression is reduced or prevented altogether. Ribozymes will be designed to cleave mRNA encoded by an GPR39 GPCR encoding nucleic acid sequence of the invention, desirably at a target sequence specific to the 35 GPR39 GPCR, i.e one which is not common to other GPCR WO 2006/058889 PCT/EP2005/056350 -15 sequences. The construction of antisense sequences and their use is described in Peyman and Ulman, Chemical Reviews, 90:543-584, (1990), Crooke, Ann. Rev. Pharmacol. Toxicol., 32:329-376, (1992), and Zamecnik and 5 Stephenson, P.N.A.S, 75:280-284, (1974). The construction of ribozymes and their use is described in for instance Gibson and Shillitoe, Molecular Biotechnology 7(2): 125 137, (1997). 10 In one embodiment, RNA of the invention can be used for induction of RNA interference (RNAi), using double stranded (dsRNA) (Fire et al., Nature 391: 806-811. 1998) or short-interfering RNA (siRNA) sequences (Yu et al., Proc Natl Acad Sci USA. 99:6047-52. 2002). "RNAi" is the 15 process by which dsRNA induces homology-dependent degradation of complimentary mRNA. In one embodiment, a nucleic acid molecule of the invention is hybridized by complementary base pairing with a "sense" ribonucleic acid of the invention to form the double stranded RNA. The 20 dsRNA antisense and sense nucleic acid molecules are provided that correspond to at least about 20, 25, 50, 100, 250 or 500 nucleotides or an GPR39 coding strand, or to only a portion thereof. In an alternative embodiment, the siRNAs are 30 nucleotides or less in length, and more 25 preferably 21- to 23-nucleotides, with characteristic 2 to 3-nucleotide 3'-overhanging ends, which are generated by ribonuclease III cleavage from longer dsRNAs. See e.g. Tuschl T. (Nat Biotechnol. 20:446-48. 2002). 30 Intracellular transcription of small RNA molecules can be achieved by cloning the siRNA templates into RNA polymerase III (Pol III) transcription units, which normally encode the small nuclear RNA (snRNA) U6 or the human RNAse P RNA Hl. Two approaches can be used to 35 express siRNAs: in one embodiment, sense and antisense WO 2006/058889 PCT/EP2005/056350 -16 strands constituting the siRNA duplex are transcribed by individual promoters (Lee, et al. Nat. Biotechnol. 20, 500-505. 2002); in an alternative embodiment, siRNAs are expressed as stem-loop hairpin RNA structures that give 5 rise to siRNAs after intracellular processing (Brummelkamp et al. Science 296:550-553. 2002) (herein incorporated by reference). The dsRNA/siRNA is most commonly administered by annealing 10 sense and antisense RNA strands in vitro before delivery to the organism. In an alternate embodiment, RNAi may be carried out by administering sense and antisense nucleic acids of the invention in the same solution without annealing prior to administration, and may even be 15 performed by administering the nucleic acids in separate vehicles within a very close timeframe. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a GPR39 or antisense nucleic acids complementary to a GPR39 nucleic acid sequence are 20 additionally provided. Antisense, siRNAs and ribozyme sequences of the invention may be introduced into mammalian cells lines in culture to study the function of GPR39 GPCR, for example by causing 25 down-regulation of this gene and observing phenotypic effects, or the expression or location of proteins described herein which associate with GPR39 GPCR. In cells where aberrant expression of GPR39 GPCR occurs, such antisense, siRNA and ribozyme sequences may be used to 30 down-regulate the expression of the gene. The cDNA sequence of the GPCR of the invention may be cloned using standard PCR (polymerase chain reaction) cloning techniques. This involves making a pair of 35 primers to 5' and 3' ends on opposite strands of SEQ ID WO 2006/058889 PCT/EP2005/056350 -17 NO:1, bringing the primers into contact with mRNA or cDNA obtained from a mammalian cortical cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the 5 amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector. The same applies 10 to SEQ ID NO:3. Polynucleotides which are not 100% homologous to the sequence of SEQ ID NO:1 or SEQ ID NO:3 but which encode either SEQ ID NO:2 or SEQ ID NO:4 or other polypeptides of 15 the invention can be obtained in a number of ways. For example, site directed mutagenesis of the sequence of SEQ ID NO: 1 or SEQ ID NO:3 may be performed. This is useful where for example silent codon changes are required 20 to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of 25 the polypeptides encoded by the polynucleotides. Further changes may be desirable to represent particular coding changes which are required to provide, for example, conservative substitutions. 30 Nucleic acids of the invention may comprise additional sequences at the 5' or 3' end. For example, synthetic or natural 5' leader sequences may be attached to the nucleic acid encoding polypeptides of the invention. The additional sequences may also include 5' or 3' 35 untranslated regions required for the transcription of WO 2006/058889 PCT/EP2005/056350 -18 nucleic acid of the invention in particular host cells. In addition, other animal, particularly mammalian (e.g. humans or rabbits), more particularly primate including 5 human, homologues of GPR39 may be obtained and used in the methods of the present invention. Such sequences may be obtained by making or obtaining cDNA libraries made from dividing cells or tissues or genomic DNA libraries from other animal species, and probing such libraries with 10 probes comprising all or part of SEQ ID NO:1 or of SEQ ID NO:3 under conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50 NC to about 60N C). 15 The present invention further extends to an isolated DNA sequence comprising sequences encoding a polypeptide of the invention but in which the encoding sequences are divided up into two or more (preferably no more than five, e.g. four or three) exons. Such exon sequences may be 20 natural and obtained from genomic clones, or synthetic. Exon sequences may be used in the construction of mini gene sequences which comprise nucleic acid encoding polypeptides of the invention which sequences are interrupted by one or more exon sequences. 25 Mini-genes may also be constructed using heterologous exons, derived from any eukaryotic source. Polypeptides. 30 Isolated polypeptides used in the methods of the present invention will be those as defined above in isolated form, free or substantially free of material with which it is naturally associated such as other polypeptides with which WO 2006/058889 PCT/EP2005/056350 -19 it is found in the cell. The polypeptides may of course be formulated with diluents or adjuvants and still for practical purposes be isolated - for example the polypeptides will normally be mixed with gelatin or other 5 carriers if used to coat microtitre plates for use in immunoassays. The polypeptides may be glycosylated, either naturally or by systems of heterologous eukaryotic cells, or they may be (for example if produced by expression in a prokaryotic cell) unglycosylated. 10 Polypeptides may be phosphorylated and/or acetylated. A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in 15 which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the invention. Polypeptides of the invention may be modified for example 20 by the addition of histidine residues to assist their purification or by the addition of a signal sequence to promote their secretion from a cell. Polypeptides having at least 50%, for example 60%, 70%, 25 80%, 90%, 95% or 98% sequence identity to SEQ ID NO:2 or SEQ ID NO:4 may be polypeptides which are amino acid sequence variants, alleles, derivatives or mutants of SEQ ID NO:2 or SEQ ID NO:4 respectively, and are also provided by the present invention. For example such a polypeptide 30 may have an amino acid sequence which differs from that given in SEQ ID NO:2 or SEQ ID NO:4 by one or more of addition, substitution, deletion and insertion of one or more (such as from 1 to 20, for example 2, 3, 4, or 5 to 10) amino acids. 35 WO 2006/058889 PCT/EP2005/056350 -20 The percentage identity of polypeptide sequences can be calculated using commercially available algorithms which compare a reference sequence( e.g. SEQ ID NO:2 or SEQ ID NO:4 of the present invention) with a query sequence. 5 Further details of assessing identity are described below. Where a query sequence is determined to have an identity to that of SEQ ID NO:2 or SEQ ID NO:4 of at least 50% and preferably at least 60%, 70%, 80%, 90%, 95% or 98% said 10 sequence being that of a polypeptide retaining GPR39 receptor activity, such a sequence forms part of the present invention. A polypeptide according to the present invention may be 15 isolated and/or purified (e.g. using an antibody) for instance after production by expression from encoding nucleic acid. The isolated and/or purified polypeptide may be used in formulation of a composition, which may include at least one additional component, for example a 20 pharmaceutical composition including a pharmaceutically acceptable excipient, vehicle or carrier. A polypeptide according to the present invention may be used as an immunogen or otherwise in obtaining specific 25 antibodies. Antibodies are useful in purification and other manipulation of polypeptides, diagnostic screening and therapeutic contexts. A polypeptide according to the present invention may be 30 used in screening for molecules which bind to it or modulate its activity or function. Such molecules may be useful in a therapeutic (possibly including prophylactic) context. 35 A polypeptide or labelled polypeptide of the invention or WO 2006/058889 PCT/EP2005/056350 -21 fragment thereof may also be fixed to a solid phase, for example the surface of an immunoassay well or dipstick. Such labelled and/or immobilized polypeptides may be 5 packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like. Such polypeptides and kits may be used in methods of detection of antibodies to such polypeptides present in a 10 sample or active portions or fragments thereof by immunoassay. Immunoassay methods are well known in the art and will generally comprise: 15 (a) providing a polypeptide comprising an epitope bindable by an antibody against said protein; (b) incubating a biological sample with said polypeptide under conditions which allow for the formation of an antibody-antigen complex; and 20 (c) determining whether antibody-antigen complex comprising said polypeptide is formed. Sequence Identity 25 The percentage identity of nucleic acid and polypeptide sequences can be calculated using commercially available algorithms which compare a reference sequence with a query sequence. The following programs (provided by the National Center for Biotechnology Information) may be used 30 to determine homologies/identities: BLAST, gapped BLAST, BLASTN and PSI-BLAST, which may be used with default parameters. The algorithm GAP (Genetics Computer Group, Madison, WI) 35 uses the Needleman and Wunsch algorithm to align two WO 2006/058889 PCT/EP2005/056350 -22 complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4. 5 Another method for determining the best overall match between a nucleic acid sequence or a portion thereof, and a query sequence is the use of the FASTDB computer program based on the algorithm of Brutlag et al (Comp. App. 10 Biosci., 6; 237-245 (1990)). The program provides a global sequence alignment. The result of said global sequence alignment is in percent identity. Suitable parameters used in a FASTDB search of a DNA sequence to calculate percent identity are: Matrix=Unitary, k-tuple=4, 15 Mismatch penalty=l, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=l, Gap Penalty=5, Gap Size Penalty=0.05, and Window Size=500 or query sequence length in nucleotide bases, whichever is shorter. Suitable parameters to calculate percent identity and similarity of 20 an amino acid alignment are: Matrix=PAM 150, k-tuple=2, Mismatch Penalty=l, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=l, Gap Penalty=5, Gap Size Penalty=0.05, and Window Size=500 or query sequence length in nucleotide bases, whichever is shorter. 25 Vectors Nucleic acid sequences of the present invention may be incorporated into vectors, particularly expression 30 vectors. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, 35 introducing the vector into a compatible host cell, and WO 2006/058889 PCT/EP2005/056350 -23 growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells are described below in connection with expression vectors. 5 Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. 10 The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is 15 ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences. Suitable vectors can be chosen or constructed, containing 20 appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. Vectors may be plasmids, viral e.g. phage, phagemid or baculoviral, cosmids, YACs, BACs, 25 or PACs as appropriate. Vectors include gene therapy vectors, for example vectors based on adenovirus, adeno associated virus, retrovirus (such as HIV or MLV) or alpha virus vectors. 30 The vectors may be provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the 35 case of a bacterial plasmid or a neomycin resistance gene WO 2006/058889 PCT/EP2005/056350 -24 for a mammalian vector. Vectors may be used in vitro, for example for the production of RNA or used to transfect or transform a host cell. The vector may also be adapted to be used in vivo, for example in methods of gene therapy. 5 Systems for cloning and expression of a polypeptide in a variety of different host cells are well known. Suitable host cells include bacteria, eukaryotic cells such as mammalian and yeast, and baculovirus systems. Mammalian cell lines available in the art for expression of a 10 heterologous polypeptide include Chinese hamster ovary cells, HeLa cells, baby hamster kidney cells, COS cells and many others. Promoters and other expression regulation signals may be 15 selected to be compatible with the host cell for which the expression vector is designed. For example, yeast promoters include S. cerevisiae GAL4 and ADH promoters, S. pombe nmtl and adh promoter. Mammalian promoters include the metallothionein promoter which can be induced 20 in response to heavy metals such as cadmium. Viral promoters such as the SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art. 25 The vectors may include other sequences such as promoters or enhancers to drive the expression of the inserted nucleic acid, nucleic acid sequences so that the polypeptide is produced as a fusion and/or nucleic acid encoding secretion signals so that the polypeptide 30 produced in the host cell is secreted from the cell. Vectors for production of polypeptides of the invention of for use in gene therapy include vectors which carry a mini-gene sequence of the invention. It is accordingly an 35 object of the present invention to provide a method for WO 2006/058889 PCT/EP2005/056350 -25 treating abnormal conditions related to an under expression of GPR39 GPCR and its activity, said method comprising the use of a polynucleotide encoding a GPR39 GPCR. In particular in a method to treat increased gastric 5 emptying such as for example, dumping syndrome or increased intestinal motility such as diarrhoea, diarrhoea-IBS and mixed-IBS. In gene therapy a polynucleotide of the invention is used to effect the endogenous production of GPR39 GPCR by the relevant cells 10 in the subject. For example, a polynucleotide encoding a GPR39 GPCR may be engineered for expression in a replication defective retroviral vector as provided above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a 15 retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells in vivo 20 and expression of the polypeptide in vivo. For review of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, in Human Molecular Genetics, T. Strachan and A.P. Read, BIOS Scientific Publishers Ltd. (1996). 25 For further details see, for example, Molecular Cloning: a Laboratory Manual: 2nd edition, Sambrook et al., 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, 30 for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons, 1992. 35 WO 2006/058889 PCT/EP2005/056350 -26 Vectors may be transformed into a suitable host cell as described above to provide for expression of a polypeptide of the invention. Thus, in a further aspect the invention provides a process for preparing polypeptides 5 according to the invention which comprises cultivating a host cell transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed polypeptides. 10 Polypeptides may also be expressed in vitro systems, such as reticulocyte lysate. A further embodiment of the invention provides host cells transformed or transfected with the vectors for the 15 replication and expression of polynucleotides of the invention. The cells will be chosen to be compatible with the said vector and may for example be bacterial, yeast, insect or mammalian. The host cells may be cultured under conditions for expression of the gene, so that the encoded 20 polypeptide is produced. If the polypeptide is expressed coupled to an appropriate signal leader peptide it may be secreted from the cell into the culture medium. Following production by expression, a polypeptide may be isolated and/or purified from the host cell and/or culture medium, 25 as the case may be, and subsequently used as desired, e.g. in the formulation of a composition which may include one or more additional components, such as a pharmaceutical composition which includes one or more pharmaceutically acceptable excipients, vehicles or carriers 30 Polynucleotides according to the invention may also be inserted into the vectors described above inan antisense orientation in order to provide for the production of antisense RNA or ribozymes. 35 WO 2006/058889 PCT/EP2005/056350 -27 Assays It is an object of the present invention to provide an assay for identifying compounds that modulate 5 gastrointestinal kinetics and cholesterol homeostasis, which assay -comprises: providing all or part of a GPR39 receptor protein according to the invention, contacting said protein with a putative binding compound; and determining whether said compound is able to interact with 10 said protein. In one embodiment of the assay, the receptor or subunits of the receptor may be employed in a binding assay. Binding assays may be competitive or non-competitive. 15 Such an assay can accommodate the rapid screening of a large number of compounds to determine which compounds, if any, are capable of binding to the polypeptides. Subsequently, more detailed assays can be carried out with those compounds found to bind, to further determine 20 whether such compounds act as agonists or antagonists of the polypeptides of the invention. It is accordingly an object of the present invention to provide for a method for identifying a compound that 25 modulate gastrointestinal kinetics and cholesterol homeostasis, which method comprises: (i) contacting host cells expressing all or part of the GPR39 receptor protein according to the invention, with said compound under conditions 30 suitable for binding, and (ii) detecting binding of the compound to said receptor protein. In a further embodiment this invention provides a method 35 for identifying a compound that modulate gastrointestinal WO 2006/058889 PCT/EP2005/056350 -28 kinetics, which method comprises: (i) contacting membrane preparations from host cells expressing all or part of the GPR39 receptor protein according to the invention, with said 5 compound under conditions suitable for binding, and (ii) detecting binding of the compound to said receptor protein. 10 In a still further embodiment the present invention provides a method for identifying a compound that modulate gastrointestinal kinetics, which method involves a competitive binding assay wherein: (i) host cells expressing all or part of the GPR39 15 receptor protein according to the invention are contacted with a compound known to bind to the GPR39 receptor protein both in the presence and absence of the compound to be tested, and (ii) the effect of said compound on the binding of 20 the compound known to bind to the GPR39 receptor protein is being assessed. A decrease in the binding of the compound known to bind to the GPR39 receptor protein in the presence of the compound to be tested is an indication that said compound binds to 25 the GPR39 receptor protein. Obestatin, the natural ligand for the GPR39 receptor protein has recently been identified (Zhang, J.V. et al., 2004 Science Vol.310;996 999) as another peptide derived from the same prohormone as ghrelin. In a particular embodiment the compound known 30 to bind to the receptor consists of obestatin, more in particular selected from one of the obestatin sequences disclosed in Fig.5, i.e. selected from SEQ ID No's 8 to 19, more in particular SEQ ID No.8 or SEQ ID No.10. Alternatively the obestatin as used herein refers to a 35 peptide having at least 60%, 70%, 80%, 90%, 95%, 98% or WO 2006/058889 PCT/EP2005/056350 -29 99% sequence identity to the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:10. In an alternative embodiment, the aforementioned 5 competitive binding assay is performed on membrane preparations of host cells expressing all or part of the GPR39 receptor protein according to the invention. Methods for preparing said host cells and for preparing membrane preparations from such cells are described 10 hereinafter. In a specific embodiment the GPR39 receptor protein in the aforementioned binding assays is an isolated protein having an amino acid sequence selected from the group 15 consisting of SEQ ID No:2, SEQ ID NO:4, a splice variant of the proteins having the aforementioned SEQ ID's, and an amino acid sequence having at least 50% and preferably at least 60%, 70%, 80%, 90%, 95% or 98% sequence identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. 20 Parts of the GPR39 protein, as used hereinbefore, are meant to include fragments of the polypeptide of SEQ ID NO:2 or SEQ ID NO:4, said fragments being of at least 10, for example at least 20, 30 40, 50, 75, 100 or 150 or more 25 amino acids in size. Such fragments may be derived from the N-terminal region of SEQ ID NO:2 or SEQ ID NO:4 respectively. Fragments including the N-terminal region may be used to reconstitute the extracellular portion of the receptor to provide receptor binding sites. 30 Preferably, fragments will retain the ability to bind the compound known to bind to the GPR39 receptor protein. Membrane preparations Cell membranes expressing the receptor protein of this 35 invention are useful for certain types of assays including WO 2006/058889 PCT/EP2005/056350 -30 but not restricted to ligand binding assays, GTP-y-S binding assays and others. The specifics of preparing such cell membranes may in some cases be determined by the nature of the ensuing assay but typically involve 5 harvesting whole cells and disrupting the cell, for example by sonication in ice cold buffer (e.g. 20 mM Tris HCl, 1 mM EDTA, pH 7.4 at 4 0 C). The resulting crude cell lysate is subsequently cleared of cell debris by low speed centrifugation, for example at 200xg for 5 min at 4 0 C. 10 Further clearance and membrane enrichment is finally done using a high speed centrifugation step, such as for example 40,000xg for 20 min at 4 0 C, and the resulting membrane pellet is washed by suspending in ice cold buffer and repeating the high speed centrifugation step. The 15 final washed membrane pellet is resuspended in assay buffer. Protein concentrations are determined by the method of Bradford (1976) using bovine serum albumin as a standard. The membranes may be used immediately or frozen for later use. 20 Radiolabeled ligand binding assays Cells expressing the receptor of this invention may be used to screen for ligands for said receptor. The same assays may be used to identify agonists or antagonists of 25 the receptor that may be employed for a variety of therapeutic purposes. Radioligand binding assays are performed by diluting membranes prepared from cells expressing the receptor in an appropriate buffer, such as for example 50 mM Tris 30 buffer (pH = 7.4 at 0 0 C) containing 2.1% bovine serum albumin (Sigma), aprotinin (0.005 mg/ml, Boehringer Mannheim) and bestatin (01. mM, Sigma) as protease inhibitors. The final protein concentration in the assay is typically within 12-40 Rg/ml.

WO 2006/058889 PCT/EP2005/056350 -31 Membranes are then incubated with radiolabeled ligand either in the presence or absence of competing ligands on ice for 60 min in a total volume of 250 pl 96 well 5 microtiter plates. The bound ligand is then separated from free ligands by filtration through GF/B filters presoaked in 0.5% polyethyleneimine (PEI), using a Tomtec (Wallac) vacuum filtration device. After addition of Ready Safe (Beckman) scintillation fluid, bound radioactivity is 10 quantitated using a Trilux (Wallac) scintillation counter (approximately 40% counting efficiency of bound counts). Alternatively, it may be preferable to collect bound ligand and then separate ligand from receptor using procedures well known in the art. Data is fit to non 15 linear curves using GraphPad prism. In this manner, agonist or antagonist compounds that bind to the receptor may be identified as they inhibit the binding of the radiolabeled ligand to the membrane protein 20 of cells expressing the said receptor. Non- specific binding is defined as the amount of radioactivity remaining after incubation of membrane protein in the presence of 100 nM of the unlabeled peptide corresponding to the radioligand used. In equilibrium saturation binding 25 assays membrane preparations or intact cells transfected with the receptor are incubated in the presence of increasing concentrations of the labeled compound to determine the binding affinity of the labeled ligand. The binding affinities of unlabeled compounds may be 30 determined in equilibrium competition binding assays, using a fixed concentration of labeled compound in the presence of varying concentrations of the displacing ligands.

WO 2006/058889 PCT/EP2005/056350 -32 In a particular embodiment the aforementioned radioligand binding assay is performed using radiolabeled obestatin as defined hereinbefore. Labeling of obestatin and receptor binding has been described in Zhang, J.V. et al.(2004 5 Science Vol.310;996-999). Briefly; Iodination of obestatin was performed using the lodogen (Pierce, Upland, IN) procedure. Mixtures of the peptide (20 pg) and 1 mCi [12'I] Nal were transferred to precoated Iodogen vials and incubated for 4 min. The 1251-labeled peptide was applied to a Sep-Pak C18 cartridge (Waters) before elution with 60% acetonitrile/0.1%TFA. 10 For radioligand binding assays, rat jejunum or other tissues were washed with buffer A (20 mM Hepes, 5 mM EDTA, 1 mM dithiothreitol (DTT), 10 PM amidinophenylmethanesulfonyl fluoride, 5 mg/L leupeptin, 100 mM KCI, pH 7.5), cut into small pieces, and homogenized using a motorized homogenizer. The homogenates were centrifuged at 1,000 g for 5 min. and the supernatant was centrifuged at 300,000 g 15 for 1 hour at 2'C. The pellets (crude membrane fractions) were resuspended with buffer A without KCl, quickly frozen under liquid nitrogen, and stored at -80'C until use. Tissue homogenates were incubated in 100 pl of phosphate buffered saline containing 0.1% bovine serum albumin for 18 hours at room temperature with varying concentrations of 1 25 1-obestatin in the presence or absence of unlabeled obestatin at 20 1,000-fold excess. After incubation, the tubes were centrifuged for 10 min. at 10,000 g, and pellets were washed twice in ice-cold PBS before quantitation of radioactivity with a y-spectrophotometer. Specific binding was calculated by subtracting nonspecific binding from total binding. For displacement curves, a fixed concentration of 1_ obestatin was incubated with or without increasing concentrations of obestatin or other 25 peptides. In addition to the aforementioned binding assays, it is also an object of the present invention to provide functional assays for identifying compounds that modulate 30 gastrointestinal kinetics, characterized in that said compounds modulate the activity of the GPR39 receptor proteins according to the invention. Such an assay comprises the steps of; (i) contacting all or parts of the GPR39 receptor 35 protein with the compound to be tested, and (ii) measuring the activity of the GPR39 receptor WO 2006/058889 PCT/EP2005/056350 -33 protein, wherein the change of GPR39 activity in the presence of the test compound is an indication of the compounds capability to modulate gastrointestinal kinetics. 5 Given the observed involvement of GPR39 in cholesterol homeostasis, in all of the disclosed embodiments to identify compounds that bind to and/or modulate GPR39 activity, said assays can be used to identify compounds 10 that may affect cholesterol homeostasis in a subject, including humans and warm-blooded animals. A compound that Amodulates the activity~ of a polypeptide of the invention refers to a compound o that alters the 15 activity of the polypeptide so that it behaves differently in the presence of the compound than in the absence of the compound. Compounds affecting modulation include agonists and antagonists. An agonist encompasses a compound which activates GPR39 GPCR function. Alternatively, an 20 antagonist includes a compound that interferes with GPR39 GPCR function. Typically, the effect of an antagonist is observed as a blocking of agonist-induced receptor activation, however in the case of GPR39, which has recently been described as a constitutive active receptor, 25 the compounds that interferes with GPR39 GPCR function also include inverse agonists, i.e. agent which binds to the same receptor binding-site as an agonist for that receptor but exerts the opposite pharmacological effect. Antagonists include competitive as well as non-competitive 30 antagonists. A competitive antagonist (or competitive blocker) interacts with or near the site specific for agonist binding. A non-competitive antagonist or blocker inactivates the function of the receptor by interacting with a site other than the agonist interaction site.

WO 2006/058889 PCT/EP2005/056350 -34 It is thus an object of the present invention to provide a method for identifying compounds capable to increase gastric emptying and/or colonic motility said method 5 comprising; (i) contacting host cells expressing all or part of the GPR39 receptor protein with the compound to be tested under conditions permitting the activation of said receptor protein, and 10 (ii) detecting any increase in GPR39 receptor activity, thereby identifying the test compound as a compound capable to increase gastric emptying and/or colonic motility. 15 In a further embodiment the present invention provides a method for identifying compounds capable to decrease gastric emptying and/or colonic motility said method comprising; (i) contacting host cells expressing all or part of 20 the GPR39 receptor protein with the compound to be tested under conditions permitting the activation of said receptor protein, and (ii) detecting any decrease in GPR39 receptor activity, thereby identifying the test compound 25 as a compound capable to decrease gastric emptying and/or colonic motility. Again, as for the binding assays mentioned hereinbefore, the aforementioned activity assays can also be used to 30 identify compounds that would modulate cholesterol metabolism. Based on the observed phenotype it is to be expected that compounds that increase GPR39 activity would result in a lowering of cholesterol levels and compounds that decrease GPR39 activity would result in an increase 35 in cholesterol levels. In a particular embodiment the WO 2006/058889 PCT/EP2005/056350 -35 present invention provides a method for identifying compounds capable to decrease cholesterol levels said method comprising; (i) contacting host cells expressing all or part of 5 the GPR39 receptor protein with the compound to be tested under conditions permitting the activation of said receptor protein, and (ii) detecting any increase in GPR39 receptor activity, thereby identifying the test compound 10 as a compound capable to decrease cholesterol levels. The effect of the compounds on GPR39 activity may be an 15 increase or decrease of an intracellular second messenger formation that is mediated by GPR39 such as intracellular calcium, cAMP or a reporter gene product. GPR39 belongs to the class of proteins known as G-protein coupled receptors (GPCRs). GPCRs transmit signals across cell 20 membranes upon the binding of the ligand. The ligand bound GPCR activates intracellular signalling events mediated by heterotrimeric G proteins, such as activation of the adenylate cyclase pathway or activation of the phospholipase C-0 pathway. Assay to assess the activation 25 of the aforementioned intracellular signalling events are generally known in the art and include amongst others cell based assays for signal transduction comprising chimeric ligand-inducible transcription factors, binding assays for G-protein-coupled receptors using fluorescence intensity 30 distribution analysis, cell-signaling assays using cyclic nucleotides coupled to luminophores or measurement of responses from G protein coupled receptors using a multiple response element or cAMP response element directed reporter assay. Description of several such WO 2006/058889 PCT/EP2005/056350 -36 assays follows. The present invention also provides a bioassay for 5 identifying compounds which modulate the regulatory regions of the GPR39 GPCR gene. Such an assay is conducted utilising rat or human cells capable of expressing a polypeptide of the invention (preferably of SEQ ID NO:2 or SEQ ID NO:4). The cells are contacted with 10 at least one compound wherein the ability of said compound to modulate the regulatory region is known. Thereafter, the cells are monitored for expression of the nucleic acid of the invention. Alternatively, the promoter may be linked to a reporter gene. Suitable reporter genes that 15 may be employed include, for example, the chloramphenicol acetyltransferase gene, the luciferase gene, and the like. As understood by these of skill in the art, bioassay methods for identifying compounds that modulate the 20 activity of receptors such as polypeptides of the invention generally require comparison to a control. One type of Acontrol~ is a cell or culture that is treated substantially the same as the test cell or test culture exposed to the compound, with the distinction that the 25 Acontrol~ cell or culture is not exposed to the compound. Another type of Acontrol~ cell or culture that can be employed is a cell or culture that is identical to transfected cells, the exception that the Acontrol~ cell or culture does not express functional GPR39 GPCR. 30 Accordingly, the response of the transfected cell can be compared with that of the Acontrol~ cell or culture to the same compound under the same reaction conditions. Particularly preferred types of assays include binding WO 2006/058889 PCT/EP2005/056350 -37 assays and functional assays which may be performed as follows: Binding assays 5 Over-expression of nucleic acid encoding polypeptides of the invention in cell lines (including mammalian HEK 293 cells, CHO cells and Sf9 insect cells) may be used to produce membrane preparations bearing said polypeptides 10 (referred to in this section as GPR39 GPCR for convenience) for ligand binding studies. These membrane preparations can be used in conventional filter-binding assays (eg. Using Brandel filter assay equipment) or in high throughput Scintillation Proximity type binding 15 assays (SPA and Cytostar-T flashplate technology; Amersham Pharmacia Biotech) to detect binding of radio-labelled ligand and displacement of such radio-ligands by competitors for the binding site. Radioactivity can be measured with Packard Topcount, or similar 20 instrumentation, capable of making rapid measurements from 96-, 384-, 1536- microtitre well formats. SPA/Cytostar-T technology is particularly amenable to high throughput screening and therefore this technology is suitable to use as a screen for compounds able to displace standard 25 ligands. Another approach to study binding of ligands to GPR39 GPCR protein in an environment approximating the native situation makes use of a surface plasmon resonance effect 30 exploited by the Biacore instrument (Malmqvist M., Biochem Soc Trans. 1999 Feb;27(2):335-40). GPR39 GPCR in membrane preparations or whole cells could be attached to the biosensor chip of a Biacore and binding of ligands examined in the presence and absence of compounds to 35 identify competitors of the binding site.

WO 2006/058889 PCT/EP2005/056350 -38 Functional assays Since GPR39 GPCR acts via Gi or Go(inhibitory G protein), 5 which usually interacts with GIRK (inward rectifying potassium channels), potassium ion flux should result on activation of these receptors. This flux of ions may be measured in real time using a variety of techniques to determine the agonistic or antagonistic effects of 10 particular compounds. Therefore, recombinant GPR39 GPCR receptors expressed in cell lines or, for example, Xenopus oocytes can be characterised using whole cell and single channel electrophysiology to determine the mechanism of action of compounds of interest. Electrophysiological 15 screening, for compounds active at GPR39 GPCR, may be performed using conventional electrophysiological techniques and when they become available, novel high throughput methods currently under development. 20 Fluorescence - Calcium and sodium fluxes are measurable using several ion-sensitive fluorescent dyes, including fluo-3, fluo-4, fluo-5N, fura red, Sodium Green, SBFI and other similar probes from suppliers including Molecular Probes. Calcium and sodium influx as a result of GPR39 25 GPCR can thus be characterised in real time, using fluorometric and fluorescence imaging techniques, including fluorescence microscopy with or without laser confocal methods combined with image analysis algorithms. 30 Another approach is a high throughput screening assay for compounds active as either agonists or modulators which affect calcium transients. This assay is based around an instrument called a FLuorescence Imaging Plate Reader ((FLIPR@), Molecular Devices Corporation). In its most 35 common configuration, it excites and measures fluorescence WO 2006/058889 PCT/EP2005/056350 -39 emitted by fluorescein-based dyes. It uses an argon-ion laser to produce high power excitation at 488 nm of a fluorophore, a system of optics to rapidly scan the over the bottom of a 96-/384-well plate and a sensitive, cooled 5 CCD camera to capture the emitted fluorescence. It also contains a 96-/384-well pipetting head allowing the instrument to deliver solutions of test agents into the wells of a 96-/384-well plate. The FLIPR assay is designed to measure fluorescence signals from populations 10 of cells before, during and after addition of compounds, in real time, from all 96-/384-wells simultaneously. The FLIPR assay may be used to screen for and characterise compounds functionally active at recombinant GPR39 GPCR, eg rat or human GPR39 GPCR, expressed in cell lines. As 15 described below, calcium transients in cells transfected with GPR39 GPCR were measured using the FLIPR assay in order to measure activation of the receptors by various substrates in order to determine the natural ligand of the receptor. 20 Cyclic AMP (cAMP) assay - The receptor-mediated stimulation or inhibition of cyclic AMP (cAMP) formation may be assayed in cells expressing the receptor. An exemplary protocol for a cAMP assay is provided 25 hereinafter. In this protocol COS-7 cells are transiently transfected with the receptor gene using the DEAE-dextran method and plated in 96-well places. 48 hours after transfection, cells are washed twice with Dulbecco's phosphate buffered 30 saline (FES) supplemented with 10 mM HEPES, 10 mM glucose and 5 mM theophylline and are incubated in the same buffer for 20 min at 37 0 C, in 5% C0 2 . Test compounds are added and cells are incubated for an additional 10 min at 370C. The medium is then aspirated and the reaction stopped by 35 the addition of 100 mM HCl. The plates are stored at - WO 2006/058889 PCT/EP2005/056350 -40 20 0 C for 2-5 days For cAMP measurement, plates are thawed and the cAMP contend in each well is measured by cAMP Scintillation Proximity Assay (Amersham Pharmacia Biotech). Radioactivity is quantified using microbeta 5 Trilux counter (Wallac). Microphysiometric assay - Because cellular metabolism is intricately involved in a broad range of cellular events (including receptor activation of multiple messenger 10 pathways), the use of microphysiometric measurements of cell metabolism can in provide a generic assay of cellular activity arising from the activation of any orphan receptor regardless of the specifics of the receptor's signaling pathway. 15 General guidelines for transient receptor expression, cell preparation and microphysiometric recording are described elsewhere (Salon, J. A. and Cwicki, J. A., 1996). Typically cells expressing receptors are harvested and 20 seeded at 3 x 105 cells .per microphysiometer capsule in complete media 24 hours prior to an experiment. The media is replaced with serum free media 16 hours prior to recording to minimize non-specific metabolic stimulation by assorted and ill-defined serum factors. On the day of 25 the experiment the cell capsules are transferred to the microphysiometer and allowed to equilibrate in recording media (low buffer RPMI 1640, no bicarbonate, no serum (Molecular Devices Corporation, Sunnyvale, CA) containing 0.1-1% fatty acid free BSA), during which a vaseline 30 measurement of basal metabolic activity is established. A standard recording protocol specifies a 100 l/min flow rate, with a 2 min total pump cycle which includes a 30 sec flow interruption during which the acidification rare WO 2006/058889 PCT/EP2005/056350 -41 measurement is taken. Ligand challenges involve a 1 min 20 sec exposure to the sample just prior to the first post challenge rate measurement being taken, followed by two additional pump cycles for a total of 5 min 20 sec sample 5 exposure. Typically, drugs in a primary screen are presented to the cells at 10 pM final concentration. Follow up experiments to examine dose-dependency of active compounds are then done by sequentially challenging the 10 cells with a drug concentration range that exceeds the amount needed to generate responses ranging from threshold to maximal levels. Ligand samples are then washed out and the acidification rates reported are expressed as a percentage increase of the peak response over the baseline 15 rate observed just prior to challenge. Compounds found to modulate the activity of the polypeptides of the present invention have a number of therapeutic uses, based on the finding that GPR39 is 20 involved in the regulation of gastrointestinal kinetics and cholesterol homeostasis. In specific, this includes diseases related to delayed gastric emptying such as for example, gastroparesis post-operative ileus, gastroparesis in diabetic, functional dyspepsia, post-vagotomy 25 gastroparesis and idiopathic intestinal pseudo obstruction. Furthermore, this includes diseases related to an increased gastric emptying such as for example, dumping syndrome or increased motility such as diarrhoea, diarrhoae-IBS and mixed-IBS. Further based on the 30 observed effect on cholesterol homeostasis it also includes the metabolic syndrome with in particular cardiovascular diseases related to increased cholesterol levels such as atherosclerosis. In summary GPR39 GPCR and related receptors can be used as a valuable tool for drug WO 2006/058889 PCT/EP2005/056350 -42 development in a variety of therapeutic areas. Binding agents 5 Thus the invention further provides novel binding agents, including modulatory agents obtained by an assay according to the present invention, and compositions comprising such agents. Agents which bind to the receptor and which may have agonist or antagonist activity may be used in methods 10 of treating diseases as characterized hereinbefore, whose pathology is characterised by action via the GPR39 GPCR receptor, and such use forms a further aspect of the invention. 15 The agents may be administered an effective amount of an agent of the invention. Since many of the above-mentioned conditions are chronic and often incurable, it will be understood that Atreatment~ is intended to include achieving a reduction in the symptoms for a period of time 20 such as a few hours, days or weeks, and to include slowing the progression of the course of the disease. Such agents may be formulated into compositions comprising an agent together with a pharmaceutically acceptable 25 carrier or diluent. The agent may in the form of a physiologically functional derivative, such as an ester or a salt, such as an acid addition salt or basic metal salt, or an N or S oxide. Compositions may be formulated for any suitable route and means of administration. 30 Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, inhalable, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, WO 2006/058889 PCT/EP2005/056350 -43 intrathecal and epidural) administration. The choice of carrier or diluent will of course depend on the proposed route of administration, which, may depend on the agent and its therapeutic purpose. The formulations may 5 conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general 10 the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shapingthe product. 15 For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be 20 used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared 25 by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical 30 composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, 35 triethanolamine oleate, etc. Actual methods of preparing WO 2006/058889 PCT/EP2005/056350 -44 such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington=s Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. 5 The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated. 10 Dosage forms or compositions containing active ingredient in the range of 0.25 to 95% with the balance made up from non-toxic carrier may be prepared. 15 For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, 20 starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 25 1%-95% active ingredient, more preferably 2-50%, most preferably 5-8%. Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or 30 intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, WO 2006/058889 PCT/EP2005/056350 -45 dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying 5 agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, triethanolamine sodium acetate, etc. 10 The percentage of active compound contained in such parental compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.1% to 10% in solution are 15 employable, and will be higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably, the composition will comprise 0.2-2% of the active agent in solution. 20 It is accordingly an object of the present invention to provide a pharmaceutical composition for the treatment of delayed gastric emptying, diseases related to delayed gastric emptying such as for example, gastroparesis post operative ileus, gastroparesis in diabetic, functional 25 dyspepsia, post-vagotomy gastroparesis and idiopathic intestinal pseudo-obstruction, said composition comprising a GPR39 receptor antagonist. Another object of the invention is a pharmaceutical 30 composition for the treatment of increased cholesterol levels, increased gastric emptying, diseases related to increased gastric emptying such as for example dumping syndrome or increased intestinal motility such as diarrhoea, diarrhoea-IBS and mixed-IBS, said composition 35 comprising a GPR39 agonist.

WO 2006/058889 PCT/EP2005/056350 -46 It is accordingly an object of the present invention to provide the use of a GPR39 antagonist in the manufacture 5 of a medicament for the treatment of a disease condition related to delayed gastric emptying. In particular in the treatment of gastroparesis post-operative ileus, gastroparesis in diabetic, functional dyspepsia, post vagotomy gastroparesis and idiopathic intestinal pseudo 10 obstruction. In another embodiment the present invention provides the use of a GPR39 agonist in the manufacture of a medicament for the treatment of a disease condition related to increased gastric emptying. In particular in the treatment of dumping syndrome, diarrhoea, diarrhoea 15 IBS and mixed-IBS. This invention will be better understood by reference to the Experimental Details that follow, but those skilled in the art will readily appreciate that these are only 20 illustrative of the invention as described more fully in the claims that follow thereafter. Additionally, throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe 25 more fully the state of the art to which this invention pertains. EXAMPLES 30 The following examples illustrate the invention. Other embodiments will occur to the person skilled in the art in light of these examples. Materials and Methods 35 WO 2006/058889 PCT/EP2005/056350 -47 GPR39 knock-out mouse GPRC39 knock-out mice were obtained from Lexicon Genetics Inc. Disruption of the open reading frame of GPR39 was performed by replacing the coding region of the first 5 coding exon of the GPR39 gene with an IRES LacZ/MC1-Neo reporter gene/selection cassette. Animals were maintained in an SPF facility that meets all Belgian and European requirements for animal care. Mice were group-housed in a climate-controlled animal colony with a 12h dark-light 10 cycle (light on 7:00 EST) with free access to food and water, unless indicated differently. Adequate measures were taken to minimize pain or discomfort. All experiments were carried out in accordance with the European Communities Council Directives (86/609/EEC) and were 15 approved by the local ethical committee. Real-Time Quantitative Reverse Transcription PCR analysis of GPR39 Total RNA from different tissues dissected from wild type (brain, liver, spinal cord, stomach, kidney, spleen, 20 colon, lung, heart, oesophagus, pancreas, ileum, jejenum) and GPR39 knock-out (liver, stomach, jejenum, colon) mouse were analysed using real-time quantitative reverse transcription PCR to study the tissue distribution of GPR39 and confirm the GPR39 knock-out. 25 First strand cDNA synthesis was performed on 1,0 mg total RNA using random hexamer primers and Superscript II RT (Invitrogen Life Technologies). Quantitative PCR was performed on an ABIPrism 7000 cycler (Applied Biosystems) using a Taqman PCR kit. Serial dilutions of cDNA were 30 used to generate standard curves of threshold cycles versus the logarithms of concentrations for Z-actin. The RTQ specific primer pairs and probes are enlisted below. Mouse IMPA2 Selection of RTQ primers and probe: WO 2006/058889 PCT/EP2005/056350 -48 GPR39_FW 5'-CCA CTC ACA AGG GAC TCA ACT G-3' (SEQ ID NO:5) GPR39_REV 5'-TGG AGT TTC CAG GTT CAT CGT-3' (SEQ ID NO:6) GPR39_Probe 5'-AAC CTC TCT CGC ACC CGC CA-3' [5' FAM] [3' TAMRA] (SEQ ID NO:7) 5 Samples were run in triplicate and results are displayed only when complying with quality standards. Expression levels in the different mouse tissues are expressed as relative levels after normalisation to mouse 9 -actin 10 Staining for 9-galactosidase activity in GPR39 knock out mouse Tissues (pancreas, stomach, ileum, jejenum and colon) were dissected from homozygous GPR39 knock-out mice that express the bacterial 9-galactosidase gene (LacZ) under the regulatory control of the endogenous mouse GPR39 promoter. Whole-mount 15 staining on these tissues was performed according to described protocols (InvitroGen), tissues were next paraffin imbedded and sectioned. PHENOTYPICAL ANALYSIS Gastric emptying 20 A panel of 6 wild type and 6 homozygous male GPR39 knock out mice were housed in cages at 20-22'C, with a 14h -10h light-dark cycle. Standard commercial mouse chow (4352 Muracon G, Nutreco Belgium NV, Gent, Belgium) (4.5% fat, 4% cellulose, 21% proteins, 1.404 kcal/g) was available ad 25 libitum until the evening before the test. At 4 p.m. the food was removed and the test was started at 11 a.m. the following day. A wire-mesh plate was inserted into the bottom of the cage to avoid coprophagia during the period of fasting. Tap water was freely available at all times, 30 except during the test.

WO 2006/058889 PCT/EP2005/056350 -49 Test Meal The solid test meal, consisted of 0.1 g baked scrambled egg yolk, doped with 0.01 gCi 1 4 C-octanoic acid sodium salt (American Radiolabeled chemicals Inc, St Louis, MO, USA) 5 and mixed with 0.lg standard mice chow. Tap water was added and mixed to form a homogenous paste. Before the start of the experiments, fasted mice (19h) were trained twice weekly, for 2 weeks, on a fixed time schedule, to eat spontaneously the test meal, without the radioactive 10 marker. After this training the test meal was ingested within 60s by most of the animals. Breath Test Procedure: CO 2 sampling Six airtight plastic tubes were adapted with an inlet 15 valve through which a continuous airflow (80% N 2 , 20% 02, 360 ml/min) passed, while the air outflow was bubbled through a vial containing the CO 2 trapper, tetramethylammoniumhydroxide (1.3 mmol) (Acros, Geel, Belgium), and the pH indicator thymolphtaleine (0.006%). 20 With the sampling time used no decoloration was observed indicating that all CO 2 expired during the experiments was captured. The dimensions of the tube (diameter 50mm, length 150mm) allowed free movement of the mice. Each mouse was placed in an airtight tube and before giving the 25 test meal a baseline breath sample (5 min) was taken. The tubes were opened, the food was given to the mouse and the tube was closed again. Sampling occurred every 5 minutes during the first half hour and every 15 min during the next 4h. Scintillation liquid was added and the samples 30 were counted in a -counter. Data analysis Using least-square analysis, 4CO 2 excreted in breath was WO 2006/058889 PCT/EP2005/056350 -50 fitted by two mathematical formulae to derive the curve of the best fit (Ghoos et al., 1993 ; Maes et al., 1994): Formula 1 y = mke-kt (1-e-kt)0-1 Formula 2 y = at e-t 5 y is the percentage of ' 4 C0 2 excretion in breath per hour, t is the time in hours; m, k, P, a, b and c are regression estimated constants, with m the total amount of 1 4 C0 2 recovered when time is infinite. From the best fit the following parameters were 10 calculated: -Gastric half excretion time (ti, 2 ), time at which 50% of the total amount of 14 C0 2 was excreted. The t 1

/

2 -value therefore not only contains the gastric half emptying time but also includes the time necessary for postgastric 15 processes such as absorption and metabolism of the 1 4 C octanoic acid and the excretion of 14 CO 2 in the breath. Formula 1: t 1

/

2 = (-1/k)*ln(1-21/P) Formula 2: t 1

/

2 = 60*(b/c) 20 _The lag phase (tiag), delay in gastric emptying due to the time required for the stomach to grind the meal in fine particles. Formula 1: tiag=ln (S)/k Formula 2: tlag = 60*gammainv(0.5;1+b;1/c) 25 In order to ensure that the measured ' 4 C0 2 production did not diverge too much from the fitted mathematical curve, measured values were correlated with values mathematically fitted to the theoretical curve. If the correlation coefficient was less than 0.95 (r 0.95) the mathematical 30 fitting was not considered as acceptable and the data were rejected from analysis.

WO 2006/058889 PCT/EP2005/056350 -51 GASTRIC SECRETION A panel of 6 wild type (WT) and 6 homozygous GPR39 knock out (GPR 39-) female mice were used to investigate the gastric secretion. 5 Mice were anesthetized using isoflurane. Under anesthesia the pylorus was closed by means of a suture (vicryl 4-0, Ethicon) then the abdominal cavity was sutured. The animal was replaced individually in its cage for 4h. Four hours after the pylorus closing mice were sacrificed 10 and the esophagus was closed just above the cardia. The stomach was withdraw from the abdominal cavity. The stomach was weighed and opened to take the gastric secretion. The gastric secretion was measured and then diluted in 5 ml of water (Water Molecular Biology Grade, 15 Eppendorf). The .pH was measured using a pH electrode (pH 597, Profi Lab). Data analysis Data are expressed as means ± SD. Mice and stomach weight 20 and gastric secretion were compared between wild type (WT) and GPR39 mice using a non parametric Wilcoxon test. The pH of water (5 ml) was firstly measured then added to the gastric secretion and the pH was again measured. The difference between the pH of water and the pH of solution 25 with gastric secretion was calculated and then reported to 1 ml of the solution and then compared between both groups using a non parametric Wilcoxon test. FAEcAL PELLETS PROPULSION 30 A panel of 6 wild type (WT) and 6 homozygous GPR39 knock out (GPR 39/) male mice were used to investigate the fecal pellets propulsion. Mice were asphyxiated by CO 2 followed by decapitation. The WO 2006/058889 PCT/EP2005/056350 -52 colon was cut out from the caecum till the rectum, and freed of adhering tissues. The tissue was transferred to a glass beaker containing 100 ml of Krebs-Henseleit solution, gassed with a mixture of 95 % 02 and 5.% C 02 5 and maintained at 370 C. Prior to the start of the experiment, the length of the colon was measured. The pellets in the colon were counted and their distance to the rectum was measured. Then the time to expulsion of each pellet was recorded for 20 min. 10 Data analysis The distribution of the pellets over the length of the colon at t=0 and 20 min was determined by binning the 15 position of each pellet relative the length of the colon (bins of 15% of colon length: 0%-15%, >15%-30%, >30%-45%, >60%-75%, >75%-90% and >90%-100%, where 0% represented the rectum and 100% the IC-valve). Bins of 15% of total colon length were considered, and the number of pellets in each 20 bin and expelled from each bin was counted during a 20 min period. Statistical analysis was performed using a 2-sided Sign Test 25 Mouse behavioural tests A panel of 14 wild type and 14 homozygous male GPR39 knock-out mice and 12 wild type and 12 homozygous female GPR39 knock-out mice, were subjected to two behavioural tests: Open Field Test (an art known method to evaluate 30 locomotor activity) and Elevated Zero Maze (an art known method to evaluate anxiety-related behaviour) The Open Field Test (OFT) was performed during the light phase of a normal light/dark cycle. Each mouse was WO 2006/058889 PCT/EP2005/056350 -53 subjected to a 30-min testing session in an automated open field system. Locomotion in the horizontal and vertical pane was recorded. During this session, the following parameters were recorded: duration of moves, number of 5 moves, total distance traveled, distance traveled in the centre, distance traveled in the margin, relative distance traveled in the centre, time spent in the centre, time spent in the margin, relative time spent in the centre, distance traveled in centre vs. distance traveled in 10 margin, time spent in the centre vs. time spent in the margin, number of rearings, and duration of rearing. A Single Factor ANOVA was used as statistical analysis of the results obtained. 15 The Elevated Zero Maze (0-maze) was performed during the light phase of a normal light/dark cycle. Each mouse was subjected to a 5-min testing session in the elevated zero maze. During this session, the following parameters were recorded: move time in closed and open arms, the relative 20 time spent in closed and open arms, total distance traveled, distance traveled in closed and open arms. A Single Factor ANOVA was used as statistical analysis of the results obtained. 25 Respiratory rate A panel of six wild type and six homozygous male GPR39 knock-out mice were habituated to AIN-93G Rodent Purified Diet (Dyets, Inc., USA) prior to putting them into the metabolic cages. Mice were individually housed in type-2 30 cages under the same conditions as for the metabolic cages (see below) for a minimum of 1 week prior to measurement. For two consecutive days, all mice were housed individually in metabolic cages under controlled temperature (28.8 0 C), humidity (55-60 %) and light (12:12 WO 2006/058889 PCT/EP2005/056350 -54 h light/dark cycle, lights on 06:00 h). The animals had free access to rodent chow and water. The following parameters were measured and expressed as mean: respiratory quotient (RER), V02 and heat production. 5 BLOOD ANALYSIS Plasmatic level of cholesterol and triglycerides were determined in 6 month old male and female GPR39' mice 10 versus GPR39+/+ littermates after 12h food deprivation after a ad libitum availability of a standard chow diet. Cholesterol and triglyceride levels were determined by means a Hitachi Modular random access analyzer (Roche Diagnostics, Basel, Switzerland) using reagents and test 15 methods from the same supplier. FOOD INTAKE Cumulative food intake analysis during 6h in ad libitum fed and fasted young (17 weeks) and old (56 weeks) GPR39-' 20 mice and GPR39+/* littermates (n=6 per group) was started at 10 a.m. Each mouse was put in an individual cage, placed in a dark room (unless stated otherwise), where it received a pre-weighed amount of food. Cumulative food intake was measured by subtracting the uneaten food at 30 25 min, 1, 2, 3, 4, 5 and 6 hours. RESULTS 30 Real-Time Quantitative Reverse Transcription PCR analysis of GPR39. Real-Time Quantitative Reverse Transcription PCR of GPR39 in multiple mouse tissues derived from wild type mice showed a wide tissue distribution (Fig. 1A). Real-Time 35 Quantitative Reverse Transcription PCR of GPR39 in four WO 2006/058889 PCT/EP2005/056350 -55 different tissues (liver, stomach, jejunum, colon) derived from wild type mice and heterozygote and homozygote GPR39 knock-out mice confirmed the absence of the GPR39 transcript in the GPR39 knock-out mouse. Intermediate 5 levels were obtained in the heterozygote mice (Fig. 1B). Staining for S-galactosidase activity in GPR39 knock-out mouse Expression of GPR39 was detected in the exocrine (Islets of Langerhans) and endocrine portion of the pancreas, the 10 parietal cells located in the upper region of the mucosal glandular tissue in the pylorus and in the mucous neck cells in the corpus of the stomach, the enterocytes in the small intestine and the colon as well as in the neurons that innervate the muscle layers of the intestine. 15 Gastric emptying The gastric emptying of a solid meal in GPCR 39 knock-out mice is significantly accelerated in comparison with the wild type mice. Indeed the half emptying time (t %) in 20 GPCR 39 knock-out mice (48.5 ±2 min, n=6) is significantly decreased in comparison with wild type mice (89.9±6 min, n=6) (Fig. 2.A). The Tiag is also significantly decreased in GPCR 39 knock-out mice vs. wild type mice (22.5±1.3 min vs. 39.2±3.4 min, n=6) confirming the acceleration of 25 gastric emptying of a solid meal in GPR39 knock-out mice (Fig. 2.B). These results are mean of three consecutive tests in 6 mice per group at 3 days interval. GASTRIc SECRETION 30 No difference in mice weight was observed between WT and GPR39' mice (30.4±6.6 g vs. 26.9±4.0 g, respectively) . A trend in stomach weight between both groups was measured (WT: 978±262 mg vs. GPR39-~: 1395±343 mg; P=0.0547).

WO 2006/058889 PCT/EP2005/056350 -56 Gastric secretion (pL) was significantly increased in GPR39< mice in comparison with WT mice (638±336 pL vs. 225±170 pLL, respectively; P=0.0242). The pH decrease between water pH and gastric secretion solution pH in 5 GPR39' was significantly smaller than in WT (0.9±0.2 vs. 1.1±0.2, respectively; P=0.0374). These data suggest that the deletion of GPR39 receptor induces a significant increase of stomach secretion but this increase is not due to an increase of acid secretion. 10 FAECAL PELLETS PROPULSION The results show that distribution of pellets over the colon at the start of the experiment was not different 15 between GPR39~ ~ and WT (p=0.5637 by 2-sided Sign Test; blue bars) (Fig. 3). Pellets most proximal to the rectum (0-30% of total length) were expelled in both WT and GPR39; the majority of distally located pellets (30-75% of length) were expelled from colon of GPR39'-animals, 20 but not from WT-animals (p=0.0253; yellow bars) (Fig 3). These results indicate a more effective expulsion of faecal pellets from colon of GPR39' animals. Mouse behavioural tests 25 Since the observed differences in gastric emptying could be confounded by a difference in general activity or emotional status of the GPR39 knock-out animals, we performed a neurological examination existing of an open field test (OFT) and zero maze test (0-maze). 30 Open Field test No difference in motor activity was observed between female GPR39 knock-out and wild type littermates. Thus the WO 2006/058889 PCT/EP2005/056350 -57 observed difference in the gastric emptying is no artefact due to an increased general activity in the female GPR39 knock-out mice. No significant difference was observed in duration of moves, number of moves, total distance 5 traveled, total time traveled, distance traveled in the centre, distance traveled in the margin, relative distance traveled in the centre, time spent in the centre, time spent in the margin, relative time spent in the centre, distance traveled in centre vs. distance traveled in 10 margin, time spent in the centre vs. time spent in the margin, velocity, number of rearings, and duration of rearing. When comparing male GPR39 knock-out and wild type littermates no increase in general activity that can confound the observed difference in gastric emptying was 15 observed. If anything a small but significant decreased general activity was observed in the male GPR39 knock-out mice as evident from a significant decrease in the total move time and the total distance traveled (ANOVA, p<0.001) in male GPR39 knock-out mice compared to wild type 20 controls. In addition the distance traveled in the centre, the relative distance traveled in the centre and the centre vs. margin distance is significantly lower in GPR39 knock-out mice compared to wild type littermates. The latter differences may be due to the reduced locomotor 25 activity or, alternatively, may reflect an anxiogenic phenotype. Therefore the 0-maze test was performed. Zero maze test In the 0-maze the GPR39 knock-out mice did not display an 30 anxiogenic nor an anxiolytic phenotype. Both the relative time spend in the closed versus open arm as well as the relative distance traveled in the open versus closed arms was similar in the GPR39 knock-out and wild type control mice. Thus the increased rate in gastric emptying in the 35 GPR39 knock-out mice is not due to changed response to WO 2006/058889 PCT/EP2005/056350 -58 anxiety inducing conditions. Respiratory rate During the two recording days no difference in respiratory 5 rate was observed between male GPR39 knock-out and wild type littermates. Thus the observed difference in the gastric emptying is no artefact due to an respiratory rate in the female GPR39 knock-out mice. The respiratory quotient remained around 1.0 for both wild type and GPR39 10 knock-out mice and the V02 together with heat production did not change with genotype either. Blood analysis Blood chemistry data were collected in 6 month old male 15 and female GPR39 mice versus GPR39* * littermates after 12h of food deprivation after ad libitum availability of a standard chow diet. Cholesterol levels (average in mg/dl ± SD) were significantly increased in both male (142.2 ± 29.0) and female (118.7 ± 16.2) GPR39' mice compared to 20 GPR39 '* male (107.3 ± 37.8) and female (83.5 ± 24.2) littermates (p<0.05 and p<0.001 for males and females respectively). Triglyceride levels (average in mg/dl SD) appeared increased in both male (162.5 ± 14.7) and female (84.6 ± 7.2) GPR39' mice compared to GPR39+'* male 25 (123.9 ± 20.8) and female (71.4 ± 12.0) littermates, but the differences did not reach significance. Food intake Cumulative food intake in mice (17 weeks, n=6) that had 30 free access to food before the start of the experiment was not significantly (P=0.47) different in GPR39 knock-out mice compared with wild type mice. The same observation was made in older mice (56 weeks, n=6, P=0.78). In contrast in fasted mice (19 h) cumulative food intake was WO 2006/058889 PCT/EP2005/056350 -59 significantly (P<0.0001) lower in GPR39 mice compared with wild type mice. This effect was even more pronounced in older mice (56 weeks) . Indeed, after 6h, cumulative food intake was 0.62g lower in young and l.25g in old GPR39 5 mice compared with age matched wild type mice.

WO 2006/058889 PCT/EP2005/056350 -60 References: Bradford, M.M., A rapid and sensitive method for the 5 quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72:248-254. Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, 10 Matsukura S. Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun. 2001 Jan 26;280(3):904-7. Ghoos Y, Maes B, Geypens B, Mys G, Hiele M, Rutgeerts P 15 and Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon labeled octanoic acid breath test. Gastroenterol. 1993; 104: 1640-7. Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, 20 Meguid MM, Fujimiya M. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J. 2004 Mar;18(3):439-56. Maes B, Ghoos Y, Geypens B, Mys G, Hiele M, Rutgeerts P 25 and Vantrappen G. The combined 1 3 C-glycine/ 14 C-octanoic acid breath test: a double carbon labeled breath test to monitor gastric emptying rate of liquids and solids. J. Nucl. Med. 1994; 35: 824-31. 30 McKee K K, Tan C P, Palyha 0 C, Liu J, Feighner S D, Hreniuk D L, Smith R G, Howard A D and Van der Ploeg L H T. Cloning and characterization of two human G protein coupled receptor genes (GPR38 and GPR39) related to the growth hormone secretagogue and neurotensin receptors. 35 Genomics 46: 426-434, 1997.

WO 2006/058889 PCT/EP2005/056350 -61 Trudel L, Tomasetto C, Rio M C, Bouin M, Plourde V, Eberling P and Poitras P (2002) Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric 5 postoperative ileus in rat. Am. J. Physiol. 282,G948-G952. Peeters TL. Central and peripheral mechanisms by which ghrelin regulates gut motility. J Physiol Pharmacol. 2003 Dec;54 Suppl 4:95-103. 10 Salon J.A. and Owicki J.A. Real-time measurement of receptor activity: Application of microphysiometric techniques to receptor biology. Meth. Neurosci. 1996; 25:201-224. 15 Zhang J.V., Ren P-G., Avsian-Kretchmer 0., Luo, C-W., Rauch R., Klein C., Hsueh A. J.W. (2004) Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science Vol.310;996-999. 20

Claims

1. A method to identify compounds that modulate gastrointestinal kinetics and/or cholesterol metabolism, said method comprising the use of all or part of the GPR39 receptor protein.

2. A method according to claim 1 wherein the GPR39 receptor protein is being selected from the group consisting of SEQ ID No:2, SEQ ID No:4, a splice variant of the proteins having the aforementioned SEQ ID's, and an amino acid sequence having at least 50% and preferably at least 80%, 90%, 95% or 98% sequence identity to the amino acid sequence of SEQ ID No:2 or SEQ ID No:4.

3. A method according to claim 1 wherein a part of the GPR39 receptor protein consist of a fragment of at least 10 amino acids of the polypeptide of SEQ ID No:2 or SEQ ID No:4.

4. A method for identifying a compound that modulates gastrointestinal kinetics and/or cholesterol metabolism, which method comprises: (i) contacting host cells expressing all or part of the GPR39 protein with said compounds, and (ii) detecting binding of the compound to said receptor protein

5. A method for identifying a compound that modulates gastrointestinal kinetics and/or cholesterol metabolism, which method comprises: (i) contacting membrane preparations from host cells expressing all or part of the GPR39 protein with WO 2006/058889 PCT/EP2005/056350 63 said compounds, and (ii) detecting binding of the compound to said receptor protein

6. A method according to claims 4 or 5 wherein the binding of the compound to the GPR39 receptor protein is being detected by means of a label directly or indirectly associated with the compound to be tested or in an assay involving competition with a labelled competitor.

7. A method according to claim 6 wherein the labelled. competitor is labelled obestatin.

8. A method to identify compounds that modulate gastrointestinal kinetics and cholesterol metabolism, said method comprising: (i) contacting all or parts of the GPR39 protein receptor with the compound to be tested, and (ii) measuring the activity of the GPR39 receptor protein , wherein the change of activity in the presence of the compound is an indication of the compounds capability to modulate gastrointestinal kinetics.

9. A method according to claim 8 wherein in step i), the compounds are contacted with host cells expressing all or part of the GPR39 protein as defined in claims 2 and 3.

10. A method according to claims 8 or 9 wherein the activity of the GPR39 receptor protein is being measured as the modulation of an intracellular messenger.

11. The method according to claim 10, wherein the intracellular second messenger is cAMP, calcium or a WO 2006/058889 PCT/EP2005/056350 64 reporter gene product.

12. Use of an isolated nucleic acid sequence selected from the group consisting of; (i) a nucleic acid sequence encoding all or part of the polypeptides of SEQ ID NO:2 or SEQ ID No:4, (ii) a nucleic acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:3, or (iii)a nucleic acid sequence having at least 80% sequence identity to the nucleic acid sequence of SEQ ID NO:1 or SEQ ID NO:3, in a method according to any one of claims 1 to 11.

13. Use of a vector comprising a nucleic acid sequence as defined in claim 12, in a method according to any one of claims 1, 4, 5, 8 or 9.

14. Use of a host cell comprising a nucleic acid sequence as defined in claim 12 or a vector as defined in claim 13, in a method according to any one of claims 1, 4, 5, 8 or 9.

15. A pharmaceutical composition for the treatment of delayed gastric emptying and delayed colonic motility in a human or animal comprising a GPR39 receptor antagonist.

16. A pharmaceutical composition for the treatment of increased gastric emptying and increased colonic motility in a human or animal comprising a GPR39 agonist.

17. Use of a GPR39 antagonist in the manufacture of a medicament for the treatment of a disease condition related to delayed gastric emptying and delayed colonic motility. WO 2006/058889 PCT/EP2005/056350 65

18. Use of a GPR39 agonist in the manufacture of a medicament for the treatment of a disease condition related to increased gastric emptying and increased colonic motility.

19. A pharmaceutical composition for the treatment of increased cholesterol levels in a human or animal comprising a GPR39 receptor agonist.

20. Use of a GPR39 agonist in the manufacture of a medicament for the treatment of a disease condition related to increased cholesterol levels.